ReviewNeuro-oncology2025
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.
Review in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Bridging pediatric and adult neuro-oncology: Insights into adolescents and young adults (AYA) central nervous system tumors.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.Science translational medicine · 2026Article
- Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.Pharmacological reports : PR · 2026Review
- Detection of IDH1.R132H mutant protein in plasma extracellular vesicles and its application in preoperative noninvasive precision diagnosis of glioma.BMC cancer · 2026Article
- Editorial: Navigating the landscape ofFrontiers in oncology · 2026Article
- Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial.Nature medicine · 2025Article
- Habitat subregions analysis based on neurite orientation dispersion and density imaging enhances isocitrate dehydrogenase genotyping in glioma.BMC medical imaging · 2025Article
- Central Nervous System Tumors in Adolescents and Young Adults.Current neurology and neuroscience reports · 2025Review
- Review
- OMT and tensor SVD-based deep learning model for segmentation and predicting genetic markers of glioma: A multicenter study.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Predicting overall survival in glioblastoma patients using machine learning: an analysis of treatment efficacy and patient prognosis.Frontiers in oncology · 2025Article
- Unraveling epigenetic drivers of immune evasion in gliomas: mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
- Contrast enhancement, G-CIMP subtype, andNeuro-oncology advancesArticle
Corrections and comments
- Erratum issued
Authors and funding
26 authors.
Funding
Abstract
Isocitrate dehydrogenase (IDH)-mutant gliomas are the most common malignant primary brain tumors in young adults. This condition imposes a substantial burden on patients and their caregivers, marked by neurocognitive deficits and high mortality rates due to tumor progression, coupled with significant morbidity from current treatment modalities. Although surgery, radiation therapy, and chemotherapy improve survival, these treatments can adversely affect cognitive function, quality of life, finances, employment status, and overall independence. Consequently, there is an urgent need for innovative strategies that delay progression and the use of radiation therapy and chemotherapy. The recent Federal Drug Administration (FDA) approval of vorasidenib, a brain-penetrant small molecule targeting mutant IDH1/2 proteins, heralds a shift in the therapeutic landscape for IDH-mutant gliomas. In this review, we address the role of vorasidenib in the treatment of IDH-mutant gliomas, providing a roadmap for its incorporation into daily practice. We discuss ongoing clinical trials with vorasidenib and other IDH inhibitors, as single-agent or in combination with other therapies, as well as current challenges and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.